Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Machine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsShares Issued
Ratios

Spyre Therapeutics (SYRE) Receivables - Other (2016 - 2023)

Spyre Therapeutics' Receivables - Other history spans 7 years, with the latest figure at $163000.0 for Q3 2023.

  • For Q3 2023, Receivables - Other changed N/A year-over-year to $163000.0; the TTM value through Sep 2023 reached $163000.0, changed N/A, while the annual FY2022 figure was $375000.0, 53.99% down from the prior year.
  • Receivables - Other reached $163000.0 in Q3 2023 per SYRE's latest filing, down from $1.6 million in the prior quarter.
  • In the past five years, Receivables - Other ranged from a high of $1.6 million in Q2 2023 to a low of $163000.0 in Q3 2023.
  • Average Receivables - Other over 3 years is $665800.0, with a median of $375000.0 recorded in 2022.
  • The largest YoY upside for Receivables - Other was 53.99% in 2022 against a maximum downside of 53.99% in 2022.
  • A 3-year view of Receivables - Other shows it stood at $815000.0 in 2021, then tumbled by 53.99% to $375000.0 in 2022, then plummeted by 56.53% to $163000.0 in 2023.
  • Per Business Quant, the three most recent readings for SYRE's Receivables - Other are $163000.0 (Q3 2023), $1.6 million (Q2 2023), and $330000.0 (Q1 2023).